Concord Wealth Partners’s Theriva Biologics TOVX Stock Holding History

Concord Wealth Partners’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	-$1K	–	1099
2021 Q1	$1K	Buy	+4	New	+$790	﹤0.01%	962

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Concord Wealth Partners's TOVX Position: Q2 2021 in Review

Concord Wealth Partners sold out of Theriva Biologics (TOVX) in Q2 2021, closing a stake of 4 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in TOVX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 27 funds tracked by Wall St. Rank hold TOVX as of Q2 2021.

Concord Wealth Partners reported no remaining Theriva Biologics position as of Q2 2021 after selling out during the quarter.
Concord Wealth Partners sold 4 Theriva Biologics shares in Q2 2021, an estimated $1K.
Concord Wealth Partners first reported a position in Theriva Biologics in Q1 2021 and held it in 1 quarter.
Concord Wealth Partners's Theriva Biologics position peaked at $1K in Q1 2021.
27 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2021.

Based on Concord Wealth Partners's 13F filing for Q2 2021, filed 29 Jul 2021.